


# Artificial oocyte activation: Ionophore application

Pro, evidence for clinical readiness

Thomas EBNER

Kepler University, Linz, Austria



- Conflict of Interest

---

This speaker has received payment for expert testimony for **MSD**, **Merck**, as well as **Glycotope**, and he is a consultant for **Gynemed**.

## ■ Outline

---

1. Principle of OA
2. Artificial oocyte activation (AOA)
3. Indications of ionophore use
4. Possible mechanisms of action
5. Safety issues
6. Future aspects

## ■ Principles of oocyte activation

---

### OA is one of the 6 major steps of in vivo and in vitro fertilization

1. Cumulus cell penetration
2. Sperm/oocyte binding and penetration
3. Sperm/oocyte fusion
4. Oocyte activation
5. Sperm processing
6. PN formation



### OA is a physiological process entailing

1. the **release from MII arrest** and completion of second meiotic division and
2. **modifications of the zona pellucida** to prevent polyspermy


### Sperm proteins as potential candidates for OA

1. Citrate synthase
2. Truncated form of c-kit tyrosine kinase receptor
3. Post-acrosomal WW-domain binding protein (PAWP)
4. **Phospholipase C  $\zeta$**


Kashir et al., HRU 2010, 16 (6), 690-703




■  $\text{Ca}^{2+}$  signal



- ✓ Sperm induced  $\text{Ca}^{2+}$  oscillations stimulate mitochondrial respiration
- ✓ The resulting ATP production in turn is required to maintain sperm-triggered  $\text{Ca}^{2+}$  waves




normal FERTILIZATION no




- ✓ The effectiveness of a calcium signal depends on its number, frequency, temporal modulation, and amplitude

## ■ Competency of $\text{Ca}^{2+}$ release



Calcium signalling is affected by in vitro maturation, cryopreservation, and oocyte ageing

■  $\text{Ca}^{2+}$  and mitosis



- ✓ Oscillations cease with formation of both pronuclei
- ✓ Immediately prior to each mitotic division a single  $\text{Ca}^{2+}$  peak occurs
- ✓ A close correlation between cell division and  $\text{Ca}^{2+}$  availability has been reported
- ✓ Sinusoidal  $\text{Ca}^{2+}$  fluctuations observed shortly before every mitotic division disappeared progressively in arrested human embryos
- ✓ Mitosis can be stopped using chelators








■ Artificial oocyte activation (AOA)

I. Modified ICSI-technique

II. Electrical activation

III. **Chemical activation**

Less effective  
Limited to some species  
Meiotic spindle disruption



- ✓ Strontium chloride (Kishikawa et al., 1999)
- ✓ Puromycin (Murase et al., 2004)
- ✓ 6-DMAP (Heindryckx et al., 2009)
- ✓ Phorbol esters (Cuthbertson and Cobbold, 1995)
- ✓ Thimerosal (Fissore et al., 1995)
- ✓ Calcium ionophore (Rybouchkin et al., 1997)
  - ionomycin
  - calcimycin (A23187)

# ■ Indications

Reproductive BioMedicine Online (2015) 30, 359-365

**Live birth after artificial oocyte activation using a ready-to-use ionophore: a prospective multicentre study**

Thomas Ebner <sup>a,\*</sup>, Markus Montag <sup>b,1</sup>, on behalf of the Oocyte Activation Study Group

**Complete fertilization failure in previous ICSI cycle(s)**

Reproductive BioMedicine Online (2012) 24, 521-526

**The benefit of artificial oocyte activation is dependent on the fertilization rate in a previous treatment cycle**

Markus Montag <sup>a,b,\*</sup>, Maria Köster <sup>b</sup>, Katrin van der Ven <sup>b</sup>, Ulrike Bohlen <sup>b</sup>, Hans van der Ven <sup>b</sup>

**Low fertilization rate (<30%) in previous ICSI cycle(s)**

<sup>a</sup> Department of Gynecological Endocrinology and Fertility Disorders, University of Heidelberg, Voßstr. 9, 69115 Heidelberg, Germany; <sup>b</sup> Department of Gynecological Endocrinology and Reproductive Medicine, University of Bonn, Bonn, Germany

**Application of a ready-to-use calcium ionophore increases rates of fertilization and pregnancy in severe male factor infertility**

**Severe male factor (crypto- and azoospermia)**

Thomas Ebner, Ph.D.,<sup>1</sup> Maria Köster, Ph.D.,<sup>2</sup> Omar Shebl, M.D.,<sup>3</sup> Marianne Moser, Ph.D.,<sup>4</sup> Hans Van der Ven, M.D.,<sup>5</sup> Gernot Teus, M.D.,<sup>6</sup> and Markus Montag, Ph.D.<sup>1,6</sup>

<sup>1</sup> Landes-Frauen- und Kinderklinik, Kinderversuchszentrum, Linz, Austria; <sup>2</sup> Gynecological Endocrinology and Reproductive Medicine, University of Bonn, Bonn; and <sup>3</sup> Gynecological Endocrinology and Fertility Disorders, University of Heidelberg, Heidelberg, Germany

J Assist Reprod Genet  
DOI 10.1007/s10815-015-0486-2

CASE REPORT

**Healthy twin live-birth after ionophore treatment in a case of theophylline-resistant Kartagener syndrome**

**Severe male factor (Kartagener syndrome)**

T. Ebner<sup>1,2</sup>, M. Maurer<sup>2,3</sup>, P. Oppelt<sup>1,3</sup>, R. B. Mayer<sup>1,3</sup>, H. C. Duba<sup>2,3</sup>, W. Costamoling<sup>4</sup>, O. Shebl<sup>1,3</sup>

Human Reproduction, Vol.30, No.1 pp. 97-102, 2015

human reproduction ORIGINAL ARTICLE Infertility


**Treatment with Ca<sup>2+</sup> ionophore improves embryo development and outcome in cases with previous developmental problems: a prospective multicenter study**

T. Ebner<sup>1,2,\*</sup>, P. Oppelt<sup>1,2</sup>, M. Wöber<sup>3</sup>, P. Staples<sup>4</sup>, R.B. Mayer<sup>1,2</sup>, U. Sonnleitner<sup>5</sup>, S. Buffon-Vogel<sup>6</sup>, I. Gruber<sup>7</sup>, A.E. Haid<sup>1,2</sup>, and O. Shebl<sup>1,2</sup>

**Developmental arrest, delay, and problems**

- Theoretical mechanism of action?

- ✓ The downstream protein CaMKII oscillates in temporal synchrony with the repetitive Ca<sup>2+</sup>-peaks



This indicates that artificial Ca<sup>2+</sup> recruitment can result in a proper downstream response

- Theoretical mechanism of action?

---

- ✓ **CaMKII activity rises and falls with the initial  $\text{Ca}^{2+}$  transient in a directly proportional manner** (Markoulaki et al., 2003)

This reflects the situation commonly found in artificial oocyte activation (which is the presence of a single  $\text{Ca}^{2+}$  peak)

- ✓ **Once activated autophosphorylation of CaMKII keeps the enzyme active even without the presence of calcium** (Johnson et al., 1998)

This scenario would explain how a single calcium stimulus can be transmitted without a physiological repetitive pattern

- ✓ **In human, a reduction in frequency can be compensated by both a higher amplitude as well as a longer total duration of the  $\text{Ca}^{2+}$  signal** (Nikiforaki et al., 2014)

Oocyte activation is tolerant to perturbations of the  $\text{Ca}^{2+}$  oscillation pattern as long as the total calcium amount is uncompromised (and passes a critical threshold)

- Safety issues

Reproductive BioMedicine Online (2015) 30, 323–324

**EDITORIAL**

## A plea for caution and more research in the 'experimental' use of ionophores in ICSI

Jonathan van Blerkom, Jacques Cohen, Martin Johnson

Reproductive BioMedicine Online (2015)

**COMMENTARY**

## Assisted yes, but where do we draw the line?

Luigia Santella <sup>a</sup>, Brian Dale <sup>b</sup>

Current Trends in Clinical Embryology 2015; 2 (4): 149-152

**Commentary**

## Oldie but Goldie or opening Pandora's box?

Thomas Ebner<sup>1,2</sup>  
Omar Shebl<sup>1,2</sup>  
Lodovico Parmegiani<sup>3</sup>

**COMMENTARY**


## Artificial oocyte activation: evidence for clinical readiness

T Ebner <sup>a,\*</sup>, M Montag <sup>b</sup>


- ✓If it is not obvious that artificial oocyte activation is needed a sibling oocyte approach should be applied
- ✓Assisted oocyte activation is not beneficial for all patients (Montag et al., 2012; Vanden Meerschaut et al.,2012)
- ✓Artificial oocyte activation still needs to be considered as experimental (but seems to be safe)

# Oldie but Goldie or opening Pandora's Box

- 5 years of ready-to-use ionophore treatment in Linz, Austria (2011-2015) -




**Ionophore applied**




**positive hCG**

18 no ET  
8 OHSS



**Live birth rate**



**Children**

i. Is the miscarriage rate higher than would normally be expected?



19.6%  
(22/112)

6x biochemical  
16x missed abortions

ii. If available for genetic analysis are the products of conception euploid or not?



iii. Do miscarriage rates occur at the same stage of gestation common after unassisted ICSI?



15 HA-  
7 HA+

12x week 5  
3x week 7  
2x week 8  
4x week 10  
1x week 18

iv. Is the incidence of minor and major congenital malformations within acceptable limits?



0.8%  
1/126

Hypoplastic left heart syndrome (major, vitrified)

# Artificial oocyte activation with calcium ionophore does not cause a widespread increase in chromosome segregation errors in the second meiotic division of the oocyte

Antonio Capalbo, Ph.D.,<sup>a,b</sup> Christian S. Ottolini, B.Sc.,<sup>c,d</sup> Darren K. Griffin, Ph.D.,<sup>d</sup> Filippo Maria Ubaldi, M.D., M.Sc.,<sup>a,b</sup> Alan H. Handside, Ph.D.,<sup>c,d,e</sup> and Laura Rienzi, B.Sc., M.Sc.<sup>a,b</sup>

**TABLE 2**

**Aneuploidies identified in normal and abnormal activated oocytes.**

Patient	Oocyte ID	aCGH analysis	SNP genotyping analysis	No. of polar PB, PN	Amplification type
Normally activated (2PB1PN and 2PB0PN)					
1	1.1	-5, -10, +20	-5, -10, +20	2PB, 1PN	SurePlex
	1.2	+11, -21	+11, -21	2PB, 1PN	SurePlex
2	2.1	+22	+22	2PB, 1PN	SurePlex
	2.3	+1	+1 <sup>a</sup>	2PB, 1PN	SurePlex
	2.5	Euploid	Euploid	2PB, 1PN	SurePlex
4	4.1	-4	-4	2PB, 1PN	SurePlex
	4.2	Euploid	Euploid	2PB, 1PN	SurePlex
	4.3	Euploid	Euploid	2PB, 1PN	SurePlex
	4.4	Euploid	Euploid	2PB, 1PN	SurePlex
5	5.1	Euploid	N/A	2PB, 1PN	SurePlex
	5.2	-13	N/A	2PB, 1PN	SurePlex
	5.3	Euploid	N/A	2PB, 1PN	SurePlex
6	6.2	Euploid	Euploid	2PB, 1PN	MDA
	6.3	Euploid	Euploid	2PB, 1PN	MDA
7	7.3	Euploid	Euploid	2PB, 1PN	MDA
	7.4	-4	-4	2PB, 1PN	MDA
	8.1	-6, -18, +20	-6, -18, +20	2PB, 1PN	MDA
8	8.2	Euploid	Euploid	2PB, 1PN	MDA
	8.3	Euploid	Euploid	2PB, 1PN	MDA
	9.1	N/A	Euploid	2PB, 1PN	MDA
10	10.1	N/A	-17	2PB, 1PN	MDA
	10.2	N/A	Euploid	2PB, 1PN	MDA
	10.3	N/A	Euploid	2PB, 1PN	MDA
	10.4	N/A	Euploid	2PB, 1PN	MDA
Normally activated 2PB0PN					
2	2.2	++15	+15	2PB, 0PN	SurePlex
3	3.1	Euploid	Euploid	2PB, 0PN	SurePlex
7	7.2	-13, +20, -22	-13, +20, <sup>a</sup> -22	2PB, 0PN	MDA
Abnormally activated					
2	2.4	-13	-13	2PB, 2PN	SurePlex
6	6.1	Euploid	N/A	1PB, >2PN	MDA
7	7.1	Euploid	N/A	2PB, 2PN	MDA
11	11.1	+1, +4, +15, +16, +17, -18, -22	N/A	2PB, 2PN	SurePlex

Note: aCGH = array comparative genomic hybridization; N/A = not available; PB = polar body; PN = pronucleus; SNP = single-nucleotide polymorphism.  
<sup>a</sup> Aneuploidies occurred following a meiosis two segregation error.

Capalbo. *Aneuploidies after artificial activation. Fertil Steril* 2015.

**100µM**

**59.3% euploid**

„There is no evidence that AOA causes a widespread increase in chromosome segregation errors in meiosis II“

## Methodology matters: IVF versus ICSI and embryonic gene expression

Phillip J Bridges<sup>a</sup>, Myoungkun Jeoung<sup>a</sup>, Heyoung Kim<sup>a</sup>, Jung Ho Kim<sup>b</sup>, Dong Ryul Lee<sup>b</sup>, CheMyong Ko<sup>a,\*</sup>, Doris J Baker<sup>a,\*</sup>

<sup>a</sup> Division of Clinical and Reproductive Sciences, University of Kentucky, Lexington, KY 40536, USA; <sup>b</sup> Fertility Center of CHA Gangnam Medical Center, CHA University, 135-080 Seoul, South Korea

SrCl<sub>2</sub>

132 genes in total  
(197 in ICSI vs IVF)

**Table 4** Functional classification of genes that differed in blastocysts derived by ICSI with chemical activation (ICSI-A) versus IVF ( $P < 0.05$ ).

Type	Function	Name	Entities	P-value
Development	Cellular	Ureteric bud branching	16	0.00469
	Neural	Peripheral nervous system development	14	0.00398
		Neural crest cell development	5	0.00798
		Organ morphogenesis	98	0.00007
	Organ	Thyroid gland development	5	0.00147
		Inner ear morphogenesis	29	0.00197
		Middle ear morphogenesis	6	0.00324
		Embryonic gut development	5	0.00792
		Pattern specification process	28	0.00890
		Structural	Cartilage development	28
Embryonic skeletal system morphogenesis			26	0.00720
Metabolism	Cellular	Lipid glycosylation	7	0.00147
		Retinol metabolic process	10	0.00297
Response	Cellular	Glial cell differentiation	10	0.00072
		Intracellular calcium ion concentration	40	0.00005
		Other	265	0.00036
Signalling	Other	Synaptic transmission	50	0.00001
		Detection of chemical stimulus involved in cell-cell signalling	93	0.00001
		Visual perception	84	0.00006
		Response to stimulus	17	0.00629
		Digestion	15	0.00840
		Acute-phase response	216	0.00000
		G-protein coupled receptor protein signalling pathway	805	0.00008
		Signal transduction	115	0.00014
		Cell surface receptor linked signal transduction	14	0.00026
		G-protein signalling, coupled to cyclic nucleotide second messenger	103	0.00115
Cell-cell signalling	5	0.00651		
Inositol phosphate-mediated signalling	10	0.00783		
G-protein signalling, coupled to cAMP nucleotide second messenger				

(Table 4 continued on next page)




ESHRE, London, 2013

**O-215 Does oocyte activation influence morphokinetic parameters of embryos: a comparative analysis using time-lapse imaging**

M. Montag, B. Toth, J. Weigert, and T. Strowitzki

*Universitäts-Frauenklinik, Abt. Gynäkol. Endokrinologie & Fertilitätsstörungen, Heidelberg, Germany*



## Neonatal and neurodevelopmental outcome of children aged 3–10 years born following assisted oocyte activation

Frauke Vanden Meerschaut <sup>a,\*</sup>, Evelien D’Haeseleer <sup>b</sup>, Hannelore Gysels <sup>c</sup>, Ylenia Thienpont <sup>c</sup>, Griet Dewitte <sup>d</sup>, Björn Heindryckx <sup>a</sup>, An Oostra <sup>d</sup>, Herbert Roeyers <sup>c</sup>, Kristiane Van Lierde <sup>b</sup>, Petra De Sutter <sup>a</sup>

**Table 3** Scores of the follow up by assessment.

Test and age group	No. of children	Norm	Score			
Cognition	21		Verbal IQ	Perfomal IQ	Full scale IQ	
WPPSI-III-NL (<7 years)	20	100	102.8 (96.4–109.2) (77–129)	105.0 (97.8–112.2) (74–142)	104.2 (97.5–110.8) (85–144)	
WISC-III-NL (>7 years)	1	100	123	130	131	
Language	20		Receptive scale	Expressive scale	Total percentile score	
RTOS (<5 years)	8	50	82.0 (63.4–100.7) <sup>a</sup> (35.5–99)	73.3 (49.4–97.2) <sup>b</sup> (30–99)	78.2 (57.2–99.2) <sup>c</sup> (33.3–99.0)	
CELF-IV-NL (≥5 years)	12	50	32.5 (7.3–57.7) <sup>a</sup> (3.6–94.5)	40.9 (16.6–65.2) <sup>b</sup> (7.1–88.5)	40.1 (16.8–63.4) <sup>c</sup> (9.1–89.7)	
Motor skills	19		Manual dexterity	Aiming and catching	Balance	Total percentile score
Movement ABC-II-NL (3–6 years)	17	50	42.0 (24.4–58.7) (1–95)	43.8 (29.5–58.0) (2–95)	41.5 (25.1–57.9) (5–91)	37.1 (22.3–52.0) (2–84)
Movement ABC-II-NL (7–10 years)	2	50	56.5 (NA) (50–63)	21.0 (NA) (5–37)	77.0 (NA) (63–91)	50.0 (NA) (37–63)
Autism screening	16		Score			
SCQ (≥2 years)	16	<15	6.4 (4.5–8.3) (0–13)			
Maladaptive behaviour screening	19		Internalizing broadband	Externalizing broadband	Total score	
CBCL (1.5–5 years)	11	<70	50.5 (42.7–58.2) (33–74)	47.6 (42.1–53.0) (35–60)	48.6 (42.5–54.8) (30–63)	
CBCL (6–18 years)	8	<70	38.4 (33.6–43.2) (33–50)	39.1 (35.0–43.2) (34–48)	37.3 (32.0–42.5) (29–45)	
TRF (1.5–5 years)	4	<70	47.5 (41.3–53.7) (44–53)	44.8 (36.8–52.7) (38–49)	45.5 (41.7–49.3) (44–49)	
TRF (6–18 years)	4	<70	43.5 (31.7–55.7) (37–52)	42.7 (40.9–44.1) (41–43)	42.5 (32.1–52.9) (33–48)	

✓ Language skills  
 ✓ Motor skills  
 ✓ Cognition  
 were found to be within expected ranges

Injection of 0.1 mol/l CaCl<sub>2</sub> together with spermatozoa during ICSI, followed 30 min later by a 2-fold exposure to 10 μmol/l ionomycin for 10 min, 30 min apart

- Future aspects

---

What to do if there is no success with ionophore treatment?

- ✓ increase exposure time
- ✓ switch to 2-fold exposure
- ✓ switch to combination of 2 ionophores (e.g., calci- and ionomycin)
- ✓ more invasive approach (e.g., direct injection of  $\text{CaCl}_2$  & x2 ionomycin)
- ✓ use recombinant PLC $\zeta$

- Summary

---

Taken together, it seems that human oocytes can respond to a wide range of intracellular  $\text{Ca}^{2+}$  signalling parameters and have a surprisingly high rate of tolerance for prolonged changes in cytosolic  $\text{Ca}^{2+}$

So far neonatal outcome is promising

**AOA is in the transition process from experimental to clinical**  
(provided that it is applied with a proper indication)

**Thank you very much for your kind attention**



Prof. Dr. Peter OPPELT  
Assoc.Prof. Dr. Omar SHEBL

Dr. Alwin HABELSBERGER  
Dr. Elisabeth RADLER  
Dr. Richard B. MAYER

Manuela PUCHNER  
Doris BRANDSTETTER  
Esther MITTERMAIR  
Laudia HADJARI